SynthesisBMC cancer2017
A systematic review of prognostic factors at the end of life for people with a hematological malignancy.
Synthesis in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- Artificial Intelligence in Hematologic Malignancies: Opportunities, Challenges, and Clinical Integration.Cureus · 2026Review
- Article
- An Analysis of Clinical and Systemic Factors Associated with Palliative Radiotherapy Delivery and Completion at the End of Life in Alberta, Canada.Current oncology (Toronto, Ont.) · 2023Article
- Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review.AAPS PharmSciTech · 2023Review
- Accuracy of clinical predictions of prognosis at the end-of-life: evidence from routinely collected data in urgent care records.BMC palliative care · 2023Observational
- Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies.Cancers · 2023Article
- Early integration of palliative care for patients with haematological malignancies.British journal of haematology · 2022Review
- Review
- Haematological malignancies implications during the times of the COVID-19 pandemic.Oncology letters · 2021Review
- Early palliative care versus standard care in haematologic cancer patients at their last active treatment: study protocol of a feasibility trial.BMC palliative care · 2020Article
- Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study.Palliative medicine · 2019Article
- Haematology nurses' perspectives of their patients' places of care and death: A UK qualitative interview study.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2019Article
- Palliative care specialists' perceptions concerning referral of haematology patients to their services: findings from a qualitative study.BMC palliative care · 2018Article
- Early integration of palliative care in hematology: an urgency for patients, a challenge for physicians.Hematology, transfusion and cell therapyReview
- Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025).Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prognosticating is needed when patients are nearing the end of life to ensure appropriate treatment decisions, and facilitate palliative care provision and transitioning to terminal care. People with a hematological malignancy characteristically experience a fluctuating illness trajectory leading to difficulties with prognosticating. The aim of this review was to identify current knowledge regarding 'bedside' prognostic factors in the final 3 months of life for people with a hematological malignancy associated with increased risk of mortality.
methodsA systematic review of the literature was performed across: PubMed; CINAHL; PsycINFO; and Cochrane with set inclusion criteria: 1) prognostic cohort studies; 2) published 2004-2014; 3) sample ≥ 18 years; 4) >50% sample had a hematological malignancy; 5) reported 'bedside' prognostic factors; 6) median survival of <3 months; and 7) English language. Quality appraisal was performed using the Quality In Prognostic Studies (QUIPS) tool. Results are reported in line with PRISMA guidelines.
resultsThe search returned 4860 studies of which 28 met inclusion criteria. Twenty-four studies were rated moderate quality, three were high quality and one study was deemed to be of low quality. Most studies were set in the ICU (n = 24/28) and were retrospective (n = 25/28). Forty 'bedside' prognostic factors were identified as associated with increased risk of mortality encompassing the following broad categories: 1) demographics; 2) physiological complications or conditions; 3) disease characteristics; 4) laboratory blood values; and 5) interventions.
conclusionsThe literature on prognosticating in the final months of life was predominantly focused on people who had experienced acute physiological deterioration and were being treated aggressively in the in-patient setting. A significant gap in the literature exists for people who are treated less aggressively or are on a palliative trajectory. Findings did not report on, or confirm the significance of, many of the key prognostic factors associated with increased risk of mortality at the end of life in the solid tumour population, demonstrating key differences in the two populations.
trial registrationThis systematic review was not registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.